Twenty‐five patients with metastatic prostate cancer resistant to primary hormone therapy, received high‐dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES‐P) in a Phase II study using established response criteria. Objective response rate was 17%, while 22% of the patients were subjectively improved. Moderate gastrointestinal toxicity was reported in 10 patients (40%). Thromboembolic complications were seen in 2 (8%). The role of high‐dose Stilphostrol in the treatment of hormone‐resistant prostate cancer is limited.
|Original language||English (US)|
|Number of pages||4|
|Publication status||Published - Aug 1 1985|
ASJC Scopus subject areas
- Cancer Research